A modest percentage reduction can become substantial when it affects one of a lab’s highest volume services.
Under the proposed Medicare Physician Fee Schedule, the global payment for CPT 88305 could decrease by approximately 4%, with an estimated 5% reduction to the technical component and 2% reduction to the professional component.
For pathology groups that perform CPT 88305 at high volume, these proposed reductions could create a meaningful financial impact. PAMA does not directly determine reimbursement for CPT 88305, but it could create additional pressure on other tests billed by the same organization under the Clinical Laboratory Fee Schedule.
What Is Changing for CPT 88305 Under the Proposed 2027 MPFS?
CPT 88305 is the highest volume surgical pathology service, making its reimbursement especially important to pathology group financial performance.
The American Society for Clinical Pathology’s analysis of the proposed 2027 Medicare Physician Fee Schedule estimates the following changes:
| CPT 88305 Service | Estimated 2027 Change |
|---|---|
| Global Payment | Approximately 4% Lower |
| Technical Component | Approximately 5% Lower |
| Professional Component | Approximately 2% Lower |
CMS has also requested feedback on whether the CPT 88305 code family may be misvalued. This creates potential uncertainty beyond the immediate 2027 payment proposal.
These reductions remain proposed and could change when CMS publishes the final 2027 Medicare Physician Fee Schedule.
Why a 4% CPT 88305 Reduction Could Have a Significant Impact?
The actual financial impact will depend on several factors:
- Annual CPT 88305 volume
- Percentage of services billed globally
- Mix of technical and professional component billing
- Medicare patient volume
- Commercial contracts tied to Medicare rates
- Current denial and underpayment rates
The larger the concentration of revenue tied to CPT 88305, the more important it becomes to model each component separately. A group that performs a high volume of technical component services, for example, could experience more pressure than one with a greater concentration of professional component billing.
Revenue cycle performance also becomes more important when reimbursement declines. Eligibility errors, preventable denials, incorrect payments, and missed appeal opportunities consume a larger portion of already compressed margins. Pathology groups need visibility into both the scheduled rate change and the revenue that is actually collected.
What Other Pathology Reimbursement Changes Should Groups Watch?
CPT 88305 is only one part of the pathology reimbursement picture. Many pathology organizations bill services under both the Medicare Physician Fee Schedule and the Clinical Laboratory Fee Schedule.
| Reimbursement Category | Payment System | Is It Directly Affected by PAMA? |
|---|---|---|
| CPT 88305 and other surgical pathology services involving physician work | Medicare Physician Fee Schedule | No |
| Clinical diagnostic laboratory tests | Clinical Laboratory Fee Schedule | Yes |
| Commercial pathology services | Individual payer contracts | Depends on contract terms |
This distinction is important because pathology groups should not apply for one projected reduction across their entire Medicare business.
CPT 88305 exposure should be modeled under the MPFS. Tests paid under the CLFS should be evaluated separately using their individual preliminary 2027 rates. Commercial contracts should also be reviewed to determine whether they reference Medicare payment levels or use Medicare based fee schedules.
How Could PAMA Still Affect Pathology Labs in 2027?
PAMA does not directly reduce CPT 88305 reimbursement, but it could reduce payment for CLFS tests performed by the same pathology organization.
CMS’s preliminary 2027 CLFS data included weighted median rates for 1,528 codes. Of those, 1,171 had lower preliminary rates than in 2026. The overall average potential change was approximately 16% lower before applying the statutory phase in protection.
The preliminary reductions vary significantly by category:
- Molecular pathology: approximately 22% lower
- Genomic sequencing: approximately 23% lower
- Chemistry: approximately 16% lower
- Microbiology: approximately 19.3% lower
- Immunology: approximately 19.3% lower
Existing CLFS tests generally cannot be reduced by more than 15% per year from 2027 through 2029. CMS expects to publish final 2027 CLFS rates in November 2026.
For pathology groups that bill both CPT 88305 and CLFS tests, the concern is not that PAMA changes the 88305 rate. The concern is that the organization could face simultaneous reimbursement pressure from two separate Medicare payment systems.
There is also an important PAMA reporting distinction. Revenue from both the CLFS and MPFS counts toward the requirement that more than 50% of an applicable laboratory’s Medicare revenue come from those fee schedules. However, the separate $12,500 low expenditure threshold must be met using Medicare CLFS revenue.
How Should Pathology Groups Prepare for 2027 Reimbursement Changes?
Pathology leaders should take five steps to understand and manage their potential exposure.
1. Quantify CPT 88305 Revenue by Component
Separate global, technical, and professional component volume. Apply the proposed percentage change to each category rather than using one blended estimate.
2. Separate MPFS and CLFS Revenue
Map major CPT and HCPCS codes to the correct Medicare payment system. This prevents PAMA related CLFS reductions from being incorrectly applied to CPT 88305 and other MPFS services.
3. Review Commercial Payer Contracts
Identify contracts that use a percentage of Medicare or otherwise reference Medicare payment levels. A Medicare reduction may influence commercial reimbursement depending on the specific contract language.
4. Monitor Expected Versus Actual Reimbursement
Track payment performance by CPT code, payer, billing component, and contract. This helps distinguish an actual fee schedule reduction from an underpayment or processing error.
5. Strengthen Denial Prevention and Recovery
Analyze denials by payer and reason, identify recurring issues, and prioritize appeals based on financial impact. When base reimbursement declines, preventing avoidable revenue loss becomes even more important.
How Quadax Helps Pathology Groups Protect Revenue
Quadax helps pathology groups understand where revenue is changing, identify where reimbursement is falling short, and act before avoidable losses become write offs.
Our connected laboratory revenue cycle solutions support pathology groups across the reimbursement process:
- Prebilling: Eligibility verification, insurance discovery, prior authorization, medical necessity, and demographic validation help prevent avoidable downstream denials.
- Billing and Claims Management: Real-time claim editing, payer-specific rules, and intelligent routing help improve claim accuracy.
- Reimbursement Management: Line-level expected versus actual payment visibility helps identify underpayments and reimbursement variance earlier.
- Denial and Appeal Management: Automated denial capture, prioritized workflows, documentation support, and targeted appeal processes help recover earned revenue.
- iQ Intelligence: Analytics, forecasting, denial intelligence, and payer performance insights help leaders identify financial risk and act sooner.
Quadax combines more than 30 years of laboratory billing expertise with more than 5,000 active payer relationships and a 99.7% first pass clean claim rate. Pathology groups can select an in-house software, outsourced billing, or hybrid operating model based on their operational needs.
As pathology reimbursement changes in 2027, protecting revenue will require more than tracking Medicare fee schedules. Organizations will need clear visibility into reimbursement by code, component, and payer, along with connected workflows that help prevent denials, identify underpayments, and recover the revenue they have earned.
Connect with Quadax to evaluate your 2027 pathology reimbursement exposure and build a more resilient revenue cycle.
Frequently Asked Questions About CPT 88305 Reimbursement
Does PAMA directly affect CPT 88305?
No. CPT 88305 is paid under the Medicare Physician Fee Schedule. PAMA establishes rates for clinical diagnostic laboratory tests paid under the Clinical Laboratory Fee Schedule.
How much could CPT 88305 reimbursement decrease in 2027?
The proposed 2027 MPFS could reduce the global payment by approximately 4%, the technical component by 5%, and the professional component by 2%. These estimates remain subject to the final 2027 rule.
Could commercial CPT 88305 reimbursement also change?
Possibly. Some commercial payer contracts reference Medicare fee schedules or reimburse services at a percentage of Medicare. Pathology groups should review individual contract terms to determine whether Medicare changes could affect commercial rates.
